FRANKFURT, Germany, February 25 /PRNewswire/ -- t2cure, a clinical stage biopharmaceutical company developing novel regenerative therapies based on autologous progenitor cells, announced today that it has appointed Dr. Petra Rueck Head of Clinical Operations.
"We are pleased to have Petra join our company", said Manfred Ruediger, CEO of t2cure. "Petra's experience in clinical research and project management will be of critical importance to t2cure as we are preparing to move our lead product into Phase III clinical trials for severe infarcts."
"It is a unique opportunity to contribute to the development of therapies that have the potential to significantly improve patient outcomes", said Petra Rueck. "t2cure's clinical candidates have demonstrated their capacity to increase the regenerative potential of tissue damaged by acute myocardial infarctions and other cardiac or peripheral vascular diseases."
Prior to joining t2cure, Dr Rueck was a project leader with ratiopharm's Biogenerix AG, Mannheim, where most recently she was responsible for a biotechnology project including the design and management of preclinical and clinical development programs. Her previous experience includes positions in clinical research management at Pfizer and Intervet. Before that, Dr. Rueck was assistant professor at Berlin University Hospital "Benjamin Franklin" (now Charite) and worked as postdoctoral researcher at INSERM, Paris. Petra Rueck received her PhD degree in pharmacology from the University of Giessen, Germany, where she studied veterinary medicine.
About t2cure GmbH
t2cure GmbH is a biopharmaceutical company engaged in the field of stem
cell-based regenerative medicine. It develops autologous bone
marrow-derived progenitor cells as regenerative therapeutics for
cardiovascular disease including ischemic heart disease (acute myocardial
infarction and chronic ischemic heart disease, non-ischemic heart failure,
peripheral arterial occlusive disease, and diabetic polyneuropathy). The
most advanced project (t2c001-AMI) has successfully passed Phase II of
clinical development and will enter Phase III soon. t2cure is privately
financed with Entrepreneurs Fund BV, Amsterdam as lead investor.
Manfred Ruediger, CEO
D-60325 Frankfurt am Main
|SOURCE t2cure GmbH|
Copyright©2008 PR Newswire.
All rights reserved